Remind me never to get in a poker game with Food and Drug Administration reviewers. Reading the agency's signals is a tough job.
Last week, I suggested that investors sit out the binary approval of Corcept Therapeutics' (NAS: CORT) Cushing's syndrome treatment, Korlym. All signs -- cryptic though they were -- pointed to a rejection.
I was wrong. Clearly. Investors who had the guts to buy are up 50% today.
But was it really that bad of a decision? I don't think so. In biotech, you have to pick your battles. When it's hard to estimate the risk, it's best to watch from the sidelines and try to learn something along the way.
Where did I go wrong on my educated guess? I assumed the lack of a priority review for Korlym was bad news. The FDA is supposed to give them to drugs that "offer major advances in treatment, or provide a treatment where no adequate therapy exists," which would seem to be an adequate description of Korlym: There are no treatments approved for Cushing's syndrome in the U.S., although Novartis' (NYS: NVS) Signifor is approved in Europe and is hot on its tail in the U.S. Ultimately though, it's the FDA's decision to offer a priority review, and with limited resources, it has to draw the line somewhere.
The FDA didn't hold an advisory panel to review Korlym, but all that tells you is that the FDA is confident with its decision; it doesn't give much of a hint about whether the decision will be positive or negative. Either way, if the agency had held an advisory panel to review the drug, investors would have gotten a sense of what the FDA was thinking. VIVUS (NAS: VVUS) and Arena Pharmaceuticals (NAS: ARNA) are currently in this same category -- it's really hard to figure out the FDA's stance on the risk-benefit analysis for their obesity drugs -- but investors will get hints at the FDA's advisory panels before the approval decisions. Playing poker is a little easier when you can see some of the dealer's cards.
Fool analysts don't think you should sit these three out, calling them the winners of the iPhone, iPad, and Android revolution. You can find out why in their free report; just click here to get yours.
At the time thisarticle was published Fool contributorBrian Orelliholds no position in any company mentioned.Click hereto see his holdings and a short bio.Motley Fool newsletter serviceshave recommended buying shares of Novartis. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.